Telomir Pharmaceuticals, Inc. Investment Income, Interest
Telomir Pharmaceuticals, Inc. (TELO) reported Investment Income, Interest of $46.18 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-13
- Telomir Pharmaceuticals, Inc. investment income, interest for the quarter ending 2026-06-30 was $46.18K, a 3290.31% increase year-over-year.
- Telomir Pharmaceuticals, Inc. investment income, interest for the quarter ending 2026-03-31 was $51.64K, a 545.55% increase year-over-year.
- Telomir Pharmaceuticals, Inc. investment income, interest for the quarter ending 2025-12-31 was $72.10K, a 921.10% increase year-over-year.
- Telomir Pharmaceuticals, Inc. investment income, interest for the quarter ending 2025-09-30 was $44.18K, a 186.06% increase year-over-year.
- Telomir Pharmaceuticals, Inc. investment income, interest for fiscal 2025 was $125.64K, a 161.76% increase from fiscal 2024.
- Telomir Pharmaceuticals, Inc. investment income, interest for fiscal 2024 was $48.00K.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $46.18K 10-Q · filed 2026-08-13 | $97.82K 10-Q · filed 2026-08-13 | $169.92K derived: sum of 3 quarters · filed 2026-08-13 | $214.10K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $51.64K 10-Q · filed 2026-05-14 | $123.74K derived: sum of 2 quarters · filed 2026-05-14 | $167.93K derived: sum of 3 quarters · filed 2026-05-14 | $169.29K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $72.10K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $116.28K derived: sum of 2 quarters · filed 2026-03-17 | $117.64K derived: sum of 3 quarters · filed 2026-08-13 | $125.64K 10-K · filed 2026-03-17 |
| 2025-09-30 | $44.18K 10-Q · filed 2025-11-10 | $45.54K derived: sum of 2 quarters · filed 2026-08-13 | $53.54K 10-Q · filed 2025-11-10 | $60.60K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $1.36K 10-Q · filed 2026-08-13 | $9.36K 10-Q · filed 2026-08-13 | $16.42K derived: sum of 3 quarters · filed 2026-08-13 | $31.87K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $8.00K 10-Q · filed 2026-05-14 | $15.06K derived: sum of 2 quarters · filed 2026-05-14 | $30.51K derived: sum of 3 quarters · filed 2026-05-14 | $56.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $7.06K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $22.51K derived: sum of 2 quarters · filed 2026-03-17 | $48.00K derived: sum of 3 quarters · filed 2026-03-17 | $48.00K 10-K · filed 2026-03-17 |
| 2024-09-30 | $15.45K 10-Q · filed 2025-11-10 | $40.94K derived: sum of 2 quarters · filed 2025-11-10 | $40.94K 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $25.49K 10-Q · filed 2025-08-14 | $25.49K 10-Q · filed 2025-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |